ANI Pharmaceuticals, Inc. (ANIP)
USD 53.88
(-3.49%)
USD 53.88
(-3.49%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 315.32 Million USD | 10.05% |
| 2022 | 286.51 Million USD | -0.3% |
| 2021 | 287.37 Million USD | 54.76% |
| 2020 | 185.68 Million USD | -0.03% |
| 2019 | 185.74 Million USD | 1.49% |
| 2018 | 183.01 Million USD | -9.18% |
| 2017 | 201.5 Million USD | 67.03% |
| 2016 | 120.64 Million USD | 6.36% |
| 2015 | 113.42 Million USD | 2.47% |
| 2014 | 110.69 Million USD | 0.0% |
| 2013 | - USD | -100.0% |
| 2012 | 7.88 Million USD | -54.53% |
| 2011 | 17.33 Million USD | -6.53% |
| 2010 | 18.54 Million USD | 11.22% |
| 2009 | 16.67 Million USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | -100.0% |
| 2000 | 500 Thousand USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 310.09 Million USD | -0.07% |
| 2024 Q1 | 310.3 Million USD | -1.59% |
| 2023 Q4 | 315.32 Million USD | 10.3% |
| 2023 Q3 | 285.88 Million USD | -0.07% |
| 2023 FY | 315.32 Million USD | 10.05% |
| 2023 Q1 | 286.3 Million USD | -0.07% |
| 2023 Q2 | 286.09 Million USD | -0.07% |
| 2022 Q3 | 286.73 Million USD | -0.07% |
| 2022 FY | 286.51 Million USD | -0.3% |
| 2022 Q1 | 287.15 Million USD | -0.07% |
| 2022 Q2 | 286.94 Million USD | -0.07% |
| 2022 Q4 | 286.51 Million USD | -0.07% |
| 2021 Q4 | 287.37 Million USD | 42.27% |
| 2021 FY | 287.37 Million USD | 54.76% |
| 2021 Q3 | 201.99 Million USD | -1.33% |
| 2021 Q2 | 204.7 Million USD | 11.6% |
| 2021 Q1 | 183.42 Million USD | -1.22% |
| 2020 Q2 | 190.2 Million USD | -4.88% |
| 2020 Q4 | 185.68 Million USD | -1.2% |
| 2020 Q3 | 187.94 Million USD | -1.19% |
| 2020 FY | 185.68 Million USD | -0.03% |
| 2020 Q1 | 199.96 Million USD | 7.65% |
| 2019 Q4 | 185.74 Million USD | -0.46% |
| 2019 FY | 185.74 Million USD | 1.49% |
| 2019 Q2 | 185.69 Million USD | 0.98% |
| 2019 Q1 | 183.89 Million USD | 0.48% |
| 2019 Q3 | 186.61 Million USD | 0.49% |
| 2018 Q2 | 204.6 Million USD | 1.03% |
| 2018 FY | 183.01 Million USD | -9.18% |
| 2018 Q4 | 183.01 Million USD | -11.06% |
| 2018 Q3 | 205.76 Million USD | 0.57% |
| 2018 Q1 | 202.53 Million USD | 0.51% |
| 2017 FY | 201.5 Million USD | 67.03% |
| 2017 Q4 | 201.5 Million USD | 33.2% |
| 2017 Q3 | 151.28 Million USD | -2.01% |
| 2017 Q2 | 154.38 Million USD | 1.23% |
| 2017 Q1 | 152.5 Million USD | 26.41% |
| 2016 Q4 | 120.64 Million USD | 1.54% |
| 2016 Q2 | 116.99 Million USD | 1.56% |
| 2016 FY | 120.64 Million USD | 6.36% |
| 2016 Q1 | 115.19 Million USD | 1.56% |
| 2016 Q3 | 118.8 Million USD | 1.55% |
| 2015 FY | 113.42 Million USD | 2.47% |
| 2015 Q1 | 112.17 Million USD | 1.34% |
| 2015 Q4 | 113.42 Million USD | -1.53% |
| 2015 Q3 | 115.19 Million USD | 1.34% |
| 2015 Q2 | 113.67 Million USD | 1.34% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q4 | 110.69 Million USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | 110.69 Million USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | 8.16 Million USD | 3.62% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | -100.0% |
| 2013 Q2 | - USD | -100.0% |
| 2012 Q4 | 7.88 Million USD | 3.83% |
| 2012 Q1 | 10.49 Million USD | -39.47% |
| 2012 FY | 7.88 Million USD | -54.53% |
| 2012 Q2 | 10.47 Million USD | -0.15% |
| 2012 Q3 | 7.59 Million USD | -27.53% |
| 2011 FY | 17.33 Million USD | -6.53% |
| 2011 Q4 | 17.33 Million USD | -15.33% |
| 2011 Q3 | 20.47 Million USD | 3.67% |
| 2011 Q2 | 19.75 Million USD | 2.95% |
| 2011 Q1 | 19.18 Million USD | 3.45% |
| 2010 Q3 | 18.36 Million USD | -0.56% |
| 2010 Q1 | 18.08 Million USD | 8.45% |
| 2010 FY | 18.54 Million USD | 11.22% |
| 2010 Q2 | 18.46 Million USD | 2.11% |
| 2010 Q4 | 18.54 Million USD | 1.0% |
| 2009 FY | 16.67 Million USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | 16.67 Million USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 Q3 | 33.48 Million USD | -45.35% |
| 2002 Q2 | 61.27 Million USD | 19.39% |
| 2002 FY | - USD | 0.0% |
| 2002 Q1 | 51.32 Million USD | 109.97% |
| 2002 Q4 | - USD | -100.0% |
| 2001 Q2 | 500 Thousand USD | 0.0% |
| 2001 Q3 | 27.4 Million USD | 5380.2% |
| 2001 Q4 | 24.44 Million USD | -10.79% |
| 2001 FY | - USD | -100.0% |
| 2001 Q1 | 500 Thousand USD | 0.0% |
| 2000 Q3 | 500 Thousand USD | 0.0% |
| 2000 FY | 500 Thousand USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q4 | 500 Thousand USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Theratechnologies Inc. | 58.96 Million USD | -434.744% |
| Harrow Health, Inc. | 190.5 Million USD | -65.525% |
| Dynavax Technologies Corporation | 256.91 Million USD | -22.737% |
| Biofrontera Inc. | 5.39 Million USD | -5740.489% |
| Cronos Group Inc. | 2.53 Million USD | -12314.791% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -51763.158% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 55.931% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -768.122% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -26782.045% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | -1611.09% |
| Radius Health, Inc. | 365.31 Million USD | 13.683% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -5651.583% |
| DURECT Corporation | 20.74 Million USD | -1419.946% |
| ProPhase Labs, Inc. | 21.38 Million USD | -1374.874% |
| Safety Shot Inc | 1.54 Million USD | -20257.217% |
| Phibro Animal Health Corporation | 525.45 Million USD | 39.99% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -11810.608% |
| Alvotech | 1.07 Billion USD | 70.68% |
| Assertio Holdings, Inc. | 40.91 Million USD | -670.747% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -659.332% |
| Rockwell Medical, Inc. | 13.43 Million USD | -2246.365% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -47843.683% |
| Procaps Group S.A. | 285.93 Million USD | -10.28% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | -1761.66% |
| SCYNEXIS, Inc. | 15.08 Million USD | -1991.034% |
| Aytu BioPharma, Inc. | 15.12 Million USD | -1984.262% |
| Viatris Inc. | 18.12 Billion USD | 98.26% |
| OptiNose, Inc. | 131.74 Million USD | -139.34% |
| SIGA Technologies, Inc. | 1.46 Million USD | -21438.665% |
| Tilray Brands, Inc. | 387.31 Million USD | 18.587% |
| PetIQ, Inc. | 468.3 Million USD | 32.666% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -47843.683% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 26.394% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Alimera Sciences, Inc. | 67.39 Million USD | -367.853% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 53.235% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -28890.507% |
| Organogenesis Holdings Inc. | 119.35 Million USD | -164.202% |
| Journey Medical Corporation | 17.73 Million USD | -1678.5% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -3709.878% |
| Alpha Teknova, Inc. | 30.45 Million USD | -935.288% |
| Clever Leaves Holdings Inc. | 2.08 Million USD | -15009.152% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | -141.89% |
| PainReform Ltd. | 86 Thousand USD | -366560.465% |
| Cosmos Health Inc. | 12.42 Million USD | -2438.065% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | -791.16% |
| TherapeuticsMD, Inc. | 8 Million USD | -3839.138% |
| Embecta Corp. | 1.63 Billion USD | 80.755% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -527142.63% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 46.194% |
| Incannex Healthcare Limited | 373 Thousand USD | -84438.338% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -30422.062% |
| Shineco, Inc. | 29.65 Million USD | -963.27% |
| Procaps Group, S.A. | 285.93 Million USD | -10.28% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | -219.087% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 48.889% |
| Alvotech | 1.07 Billion USD | 70.68% |
| Hempacco Co., Inc. | 13.72 Million USD | -2197.555% |
| Eagle Pharmaceuticals, Inc. | 62.46 Million USD | -404.799% |
| Bright Green Corporation | 1.85 Million USD | -16928.345% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 41.708% |
| Kamada Ltd. | 8.74 Million USD | -3504.166% |
| Indivior PLC | 281.6 Million USD | -11.977% |
| Evoke Pharma, Inc. | 5 Million USD | -6206.56% |
| Flora Growth Corp. | 3.67 Million USD | -8487.364% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -30422.062% |
| Evolus, Inc. | 126.54 Million USD | -149.181% |
| HUTCHMED (China) Limited | 86.13 Million USD | -266.103% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 49.438% |
| Akanda Corp. | 3.99 Million USD | -7785.583% |